# XParTS: Capecitabine/Cisplatin(XP) for Recurrent Gastric Cancer

> **NCT01412294** · PHASE2 · UNKNOWN · sponsor: **Epidemiological and Clinical Research Information Network** · enrollment: 40 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Capecitabine, Cisplatin

## Key facts

- **NCT ID:** NCT01412294
- **Lead sponsor:** Epidemiological and Clinical Research Information Network
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-07
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2017-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01412294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01412294, "XParTS: Capecitabine/Cisplatin(XP) for Recurrent Gastric Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01412294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*